Coalition for Epidemic Preparedness Innovations & Moderna

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) is a key funder, committing approximately $60 million to accelerate the development of Ebola Bundibugyo vaccines, and is crucial in coordinating the global response.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) is funding three groups, including Moderna and the University of Oxford, to accelerate the development of vaccines against the Bundibugyo strain of Ebola.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) funds vaccine development and is assessing potential Ebola vaccine candidates, aiming for a rapid response.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

Coalition for Epidemic Preparedness Innovations: CEPI is listed as a partner in the urgent coordination meeting convened by Africa CDC, indicating potential involvement in the response to the Ebola outbreak.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.